Attack of the Anthrax 'Virus'

Americans are getting a crash course in microbiology. The delivery of anthrax spores with the daily mail took the U.S. populace completely by surprise. But anyone who has read Ken Alibek's Biohazard, an account of bioweaponry in the former Soviet Union,1 or Richard Preston's fictional The Cobra Event,2 or followed periodic updates on bioterrorism here in The Scientist or in other journals, could have predicted an attempt to subvert biology into weaponry in the wake of Sept. 11. The government k

Written byRicki Lewis
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The government knew of the danger too. On Sept. 5, Donald A. Henderson, director of the Center for Civilian Biodefense Studies at Johns Hopkins University, told Congress "biological weapons are a significant threat." But once again, mainstream media are jumping on a life science story as if it sprung from the proverbial ether, much as it did for cloning in 1996 and stem cells in 1998.

While the press and public, not to mention various government officials, struggle to distinguish bacteria from viruses, antibiotics from antibodies, and viruses from vaccines, an underlying message is emerging: As a nation, our science illiteracy has gone from mere embarrassment to a life-threatening problem.

Alas, the U.S postal service's taxonomic designation of anthrax as "poison in the mail" was still the stuff of headlines in early November, conjuring up images of Snow White biting into an apple laced with bacterial spores.

Moving up the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies